ebook img

Atherosclerosis: Diet and Drugs PDF

808 Pages·2005·8.193 MB·English
Save to my drive
Quick download
Download
Most books are stored in the elastic cloud where traffic is expensive. For this reason, we have a limit on daily download.

Preview Atherosclerosis: Diet and Drugs

Handbook of Experimental Pharmacology Volume 170 Editor-in-Chief K.Starke,Freiburgi.Br. EditorialBoard G.V.R.Born,London M.Eichelbaum,Stuttgart D.Ganten,Berlin F.Hofmann,München W.Rosenthal,Berlin G.Rubanyi,Richmond,CA Atherosclerosis: Diet and Drugs Contributors J.Ahrens,M.Anthony,T.Asahara,M.Aviram,S.Bellosta, F.Bernini,C.Bode,C.Bolego,C.Bouchard,G.Chinetti, A.Cignarella,R.St.Clair,P.Cullen,A.Dendorfer,P.Dominiak, C.Fontaine,J.-C.Fruchart,B.Fuhrmann,G.Gabbiani, J.Greeve,A.K.Groen,S.Grundy,H.Hendriks,M.Hersberger, O.M.Hess,M.Kaplan,A.Kosters,K.M.Kostner,G.M.Kostner, P.Kovanen,M.Kratz,F.Kuipers,T.Lakka,T.Lüscher,F.Mach, R.Mensink,D.Müller-Wieland,R.Paoletti,K.Peters, T.Plösch,R.Robillard,M.Rosenblatt,W.Schmitz, H.Schunkert,B.Staels,R.Stocker,P.Suter,M.A.M.A.Thijssen, M.Tikkanen,A.vanTol,E.Vähäkangas,A.vonEckardstein, Q.Xu,S.Ylä-Herttuala Editor Arnold von Eckardstein 123 Professor Dr.med.ArnoldvonEckardstein InstituteofClinicalChemistry UniversityHospitalofZurich Rämistrasse100 8091Zürich Switzerland e-mail:[email protected] With78Figuresand36Tables ISSN0171-2004 ISBN-103-540-22569-2SpringerBerlinHeidelbergNewYork ISBN-13978-3-540-22569-0SpringerBerlinHeidelbergNewYork LibraryofCongressControlNumber:2004113650 Thisworkissubjecttocopyright.Allrightsreserved,whetherthewholeorpartofthematerialis concerned,specificallytherightsoftranslation,reprinting,reuseofillustrations,recitation,broad- casting,reproductiononmicrofilmorinanyotherway,andstorageindatabanks.Duplicationof thispublicationorpartsthereofispermittedonlyundertheprovisionsoftheGermanCopyrightLaw ofSeptember9,1965,initscurrentversion,andpermissionforusemustalwaysbeobtainedfrom Springer.ViolationsareliableforprosecutionundertheGermanCopyrightLaw. SpringerisapartofSpringerScience+BusinessMedia springeronline.com ©Springer-VerlagBerlinHeidelberg2005 PrintedinGermany Theuseofgeneraldescriptivenames,registerednames,trademarks,etc.inthispublicationdoesnot imply, even in theabsence of a specific statement, thatsuchnames are exempt from the relevant protectivelawsandregulationsandthereforefreeforgeneraluse. Productliability:Thepublisherscannotguaranteetheaccuracyofanyinformationaboutdosageand applicationcontainedinthisbook.Ineveryindividualcasetheusermustchecksuchinformationby consultingtherelevantliterature. Editor:Dr.P.Roos DeskEditor:S.Dathe Coverdesign:design&productionGmbH,Heidelberg,Germany Typesettingandproduction:LE-TEXJelonek,Schmidt&VöcklerGbR,Leipzig,Germany Printedonacid-freepaper 27/3150-YL-543210 Preface Cardiovasculardiseasescontinuetobetheleadingcauseofdeathinthema- jority of industrialized countries. The most frequent underlying pathology, namely atherosclerosis, and its clinicalsequelae, namely coronary heart dis- ease,cerebrovasculardiseaseandperipheralarterydisease,remaincommon although for a long time we have been made aware of avoidable or modi- fiable etiological factors such as smoking, fat-rich diet or lack of exercise, and although these adverse lifestyle factors have been extensively addressed bypopulation-wideprimarypreventionprograms.Cardiovascularmorbidity andmortalityalsoremainhighdespitesuccessfulanti-hypertensiveandlipid lowering drug therapies which help to reduce cardiovascular morbidity and mortality by about 30% in both secondary and tertiary prevention settings. Thiscanpartlybeexplainedbytheincreasinglifeexpectancyandgrowingpro- portionofelderlypeople,especiallyinEuropeandNorthAmerica.Inaddition, theWorldHealthOrganizationmakesthealarmingpredictionthatprobably inresponsetothespreadingofwesterndietarybehaviorandlackofexercise resultinginanincreasingprevalenceofdiabetes,dyslipidemiaandhyperten- sion, cardiovasculardiseasesrather thaninfectiousdiseaseswill becomethe mostfrequentcauseofdeathworldwide. This volume of the Handbook of Experimental Pharmacology entitled “Atherosclerosis” is divided into four parts and intends to give an overview onthepathogenesisofatherosclerosis,establishedtreatmentandprevention regimen,andofperspectivesforthedevelopmentofnewtreatmentmodalities. The three chapters of part I review the state-of-the-art knowledge on the pathogenesis of atherosclerosis and its underlying risk factors. Because of its increasing prevalence and corresponding public health relevance, special attentionisgiventothemetabolicsyndrome,i.e.totheclusteringofriskfactors withinagivenindividual.Althoughtheexpressionofsingleriskfactorsinthis situationmaybemoderate,affectedindividualsareathighriskforcoronary heartdiseaseevents.Inaddition,duetotheimportantetiologicalcontribution of obesity and overweight, the metabolic syndrome is an important reason whyatherosclerosiscontinuestobeasignificantpublichealthburden. TheninechaptersofpartIIaredevotedtotheroleofthevariousmajorand minor components of diet in the pathogenesis of cardiovascular risk factors andatherosclerosis.Thisfieldiscurrentlyexperiencingarenaissancefortwo VI Preface reasons:First,afterfatandnotablycholesterolhadbeenaccusedofbeing“the badguys”foralongtime,novelresearchfindingsandtheepidemicofobesity anddiabetesproducedamoredifferentiatedviewofthepathogeneticrelevance ofthevariousdietarycompounds.Second,bothdrugandfoodindustryhave discovereddietasatherapeutictargetandarecurrentlydevelopingdrugsfor thetreatmentandpreventionofoverweightandfunctionalfoodsenrichedby putativelycardioprotectivenutrients. ThefourchaptersofpartIIIgiveanoverviewofgroupsofdrugswhichin controlledinterventiontrialseffectivelypreventedatheroscleroticcardiovas- cular disease, i.e. statins, fibrates, inhibitors of the renin-angiotensin system andantiplateletagents.Unfortunately,beta-blockersarenotcovered,because theauthorinchargeofthissubjectfinallywithdrewhiscommitment. The14chaptersofpartIVpresentseveraltargetsandperspectivesfornovel pharmacologicalinterventions.Someofthesestrategiesledtothere-evaluation andoptimizationofdrugsalreadyonthemarket,forexamplenicotinicacidor agonistsofperoxisomeproliferatingagentreceptors.Otherstrategieshelpedto developdrugswhichareinphaseIIItrialsandwillprobablybeintroducedinto themarketsoon,forexampleinhibitorsofcholesterylestertransferprotein. Finally, some developments are still in the initial stage and must overcome methodological limitations, such as gene therapy. Especially for this part IV it is important to recall that atherosclerosis is a multifactorial disease which consequentlyoffersmanytargetsfortreatment.Therefore,Ihopethatwedid notleaveoutimportantdevelopments.Someauthorsunfortunatelywithdrew theiroriginalcommitmenttowriteachapterforthisbooksothat,forexample, importantcontroversiallydiscussedstrategies,likehormonereplacementand antibiotictherapies,aremissing. Lastbutnotleast,IwishtothankSpringerVerlagandtheEditorialBoard for giving me the honour and chance to edit a “Handbook of Experimental Pharmacology”onatherosclerosis.Iamverygratefultoallauthorsfor their excellentcontributions.IalsothankMrs.BernadetteHand(Zurich)forcareful language editing and Mrs. Susanne Dathe (Springer Verlag) for her patience andhelpwhileaccompanyingmethroughthisproject. Zurich,February2005 ArnoldvonEckardstein ListofContents PartI. Background ThePathogenesisofAtherosclerosis . . . . . . . . . . . . . . . . . . . . 3 P.Cullen,J.Rauterberg,S.Lorkowski RiskFactorsforAtheroscleroticVascularDisease . . . . . . . . . . . . 71 A.vonEckardstein MetabolicSyndrome:TherapeuticConsiderations . . . . . . . . . . . . 107 S.M.Grundy PartII. TheImpactofDiet PhysicalActivity,ObesityandCardiovascularDiseases . . . . . . . . . 137 T.A.Lakka,C.Bouchard FattyAcidsandAtheroscleroticRisk . . . . . . . . . . . . . . . . . . . 165 M.A.Thijssen,R.P.Mensink DietaryCholesterol,AtherosclerosisandCoronaryHeartDisease. . . . 195 M.Kratz PlantSterolsandStanols . . . . . . . . . . . . . . . . . . . . . . . . . . 215 M.J.Tikkanen CarbohydratesandDietaryFiber . . . . . . . . . . . . . . . . . . . . . 231 P.M.Suter DietaryAntioxidantsandParaoxonasesAgainstLDLOxidation andAtherosclerosisDevelopment . . . . . . . . . . . . . . . . . . . . . 263 M.Aviram,M.Kaplan,M.Rosenblat,B.Fuhrman Soy,IsoflavonesandAtherosclerosis. . . . . . . . . . . . . . . . . . . . 301 R.St.Clair,M.Anthony VIII ListofContents HomocysteineandBVitamins . . . . . . . . . . . . . . . . . . . . . . . 325 S.Cook,O.M.Hess Alcohol . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 339 H.F.J.Hendriks,A.vanTol PartIII.Evidence-BasedAnti-AtheroscleroticDrugTherapy LipidandNon-lipidEffectsofStatins . . . . . . . . . . . . . . . . . . . 365 R.Paoletti,C.Bolego,A.Cignarella Fibrates . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 389 R.Robillard,C.Fontaine,G.Chinetti,J.-C.Fruchart,B.Staels ACEInhibitorsandAngiotensinIIReceptorAntagonists . . . . . . . . 407 A.Dendorfer,P.Dominiak,H.Schunkert InhibitionofPlateletActivationandAggregation . . . . . . . . . . . . 443 I.Ahrens,C.Bode,K.Peter PartIV.TargetsofFutureAnti-AtheroscleroticDrugTherapy TheABCofHepaticandIntestinalCholesterolTransport . . . . . . . . 465 T.Plösch,A.Kosters,A.K.Groen,F.Kuipers InhibitionoftheSynthesisofApolipoproteinB-Containing Lipoproteins . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 483 J.Greeve TherapyofHyper-Lp(a) . . . . . . . . . . . . . . . . . . . . . . . . . . 519 K.M.Kostner,G.M.Kostner ModulationofHigh-DensityLipoproteinCholesterolMetabolism andReverseCholesterolTransport . . . . . . . . . . . . . . . . . . . . 537 M.Hersberger,A.vonEckardstein InhibitionofLipoproteinLipidOxidation. . . . . . . . . . . . . . . . . 563 O.Cynshi,R.Stocker CorrectionofInsulinResistanceandtheMetabolicSyndrome . . . . . 591 D.Müller-Wieland,J.Kotzka ProtectionofEndothelialFunction . . . . . . . . . . . . . . . . . . . . 619 L.E.Spieker,T.F.Lüscher ListofContents IX ModulationofSmoothMuscleCellProliferationandMigration: RoleofSmoothMuscleCellHeterogeneity . . . . . . . . . . . . . . . . 645 M.-L.Bochaton-Piallat,G.Gabbiani ModulationofMacrophageFunctionandMetabolism . . . . . . . . . . 665 S.Bellosta,F.Bernini InflammationIsaCrucialFeatureofAtherosclerosis andaPotentialTargettoReduceCardiovascularEvents . . . . . . . . . 697 F.Mach AutoimmuneMechanismsofAtherosclerosis . . . . . . . . . . . . . . . 723 K.Mandal,M.Jahangiri,Q.Xu DrugTherapiestoPreventCoronaryPlaqueRuptureandErosion: PresentandFuture . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 745 P.T.Kovanen,M.Mäyränpää,K.A.Lindstedt ReciprocalRoleofVasculogenicFactorsandProgenitorCells inAtherogenesis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 777 T.Murayama,O.M.Tepper,T.Asahara GeneTherapyofAtherosclerosis . . . . . . . . . . . . . . . . . . . . . 785 E.Vähäkangas,S.Ylä-Herttuala SubjectIndex . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 809 ListofContributors (Addressesstatedatthebeginningofrespectivechapters) Ahrens,I. 443 Jahangiri,M. 723 Anthony,M. 301 Asahara,T. 777 Kaplan,M. 263 Aviram,M. 263 Kosters,A. 465 Kostner,G.M. 519 Bellosta,S. 665 Kostner,K.M. 519 Bernini,F. 665 Kotzka,J. 591 Bochaton-Piallat,M.-L. 645 Kovanen,P.T. 745 Bode,C. 443 Kratz,M. 195 Bolego,C. 365 Kuipers,F. 465 Bouchard,C. 137 Lakka,T.A. 137 Lindstedt,K.A. 745 Chinetti,G. 389 Lorkowski,S. 3 Cignarella,A. 365 Lüscher,T.F. 619 Clair,R.St. 301 Cook,S. 325 Mäyränpää,M. 745 Cullen,P. 3 Müller-Wieland,D. 591 Cynshi,O. 563 Mach,F. 697 Mandal,K. 723 Dendorfer,A. 407 Mensink,R.P. 165 Dominiak,P. 407 Murayama,T. 777 Fontaine,C. 389 Paoletti,R. 365 Fruchart,J.-C. 389 Peter,K. 443 Fuhrman,B. 263 Plösch,T. 465 Gabbiani,G. 645 Rauterberg,J. 3 Greeve,J. 483 Robillard,R. 389 Groen,A.K. 465 Rosenblat,M. 263 Grundy,S.M. 107 Schunkert,H. 407 Hendriks,H.F.J. 339 Spieker,L.E. 619 Hersberger,M. 537 Staels,B. 389 Hess,O.M. 325 Stocker,R. 563

See more

The list of books you might like

Most books are stored in the elastic cloud where traffic is expensive. For this reason, we have a limit on daily download.